Gold Nanoparticles Indicate Early Detection of Heart Attacks
|
By LabMedica International staff writers Posted on 27 Jan 2015 |

Image: Microscopic view of microplasma-gold nanoparticles on a new, highly sensitive test strip that enables early detection of heart attacks (Photo courtesy of New York University Polytechnic School of Engineering).
A test strip for a heart attack biomarker is being developed as its level is several thousand times higher in patients experiencing myocardial infarctions. The new strip uses microplasma technology.
Cardiac troponin I (cTn-I) is a specific marker for myocardial infarction and a new cTn-I test is based on the specific immune-chemical reactions between antigen and antibody on immunochromatographic test strips using gold nanoparticles (AuNPs).
Bioengineers at the New York University Polytechnic School of Engineering used an atmospheric-pressure non-thermal microplasma for the synthesis of aqueous gold nanoparticles (AuNPs). The microplasma-induced liquid chemistry was analyzed by monitoring the pH value and the conductivity of the liquid. A sample pad made of glass fiber was saturated with 100 mM phosphate buffered saline and the anti-cardiac troponin antibody19C7 MAb (HyTest Ltd.; Turku, Finland) was conjugated to AuNPs and sprayed onto the conjugate pad. After the addition of other antibodies, the nitrocellulose membranes were combined with the conjugate pad at the opposite end downstream of the control line. The sample pad was placed on top and in front of the conjugate pad at the site of the sample application wells.
Compared to AuNPs produced by traditional chemical methods, the surfaces of the gold nanoparticles generated by the microplasma-induced liquid chemical process attracted more antibodies, which resulted in significantly higher detection sensitivity. A positive result yields reddish bands at both the test (T) and control (C) positions, whereas a negative result yields a reddish band at position C only. The level of cTn-I is below 0.06 ng/mL in the blood of healthy people, whereas the level of cTn-I may reach 100 ng/mL to 1,300 ng/mL in patients after the onset of acute myocardial infarction (AMI) and remains high for up to four to10 days.
The authors concluded that the immune-chromatography test assays for cTn-I prepared by AuNPs generated by plasma-liquid interaction exhibit higher detection sensitivity than those prepared by chemically reduced AuNPs detection. They believe that the microplasma-assisted synthesis of AuNPs have great potential for a variety of biomedical and therapeutic applications. The study was first published online on December 11, 2014, in the journal Plasma Processes and Polymers.
Related Links:
New York University Polytechnic School of Engineering
HyTest Ltd.
Cardiac troponin I (cTn-I) is a specific marker for myocardial infarction and a new cTn-I test is based on the specific immune-chemical reactions between antigen and antibody on immunochromatographic test strips using gold nanoparticles (AuNPs).
Bioengineers at the New York University Polytechnic School of Engineering used an atmospheric-pressure non-thermal microplasma for the synthesis of aqueous gold nanoparticles (AuNPs). The microplasma-induced liquid chemistry was analyzed by monitoring the pH value and the conductivity of the liquid. A sample pad made of glass fiber was saturated with 100 mM phosphate buffered saline and the anti-cardiac troponin antibody19C7 MAb (HyTest Ltd.; Turku, Finland) was conjugated to AuNPs and sprayed onto the conjugate pad. After the addition of other antibodies, the nitrocellulose membranes were combined with the conjugate pad at the opposite end downstream of the control line. The sample pad was placed on top and in front of the conjugate pad at the site of the sample application wells.
Compared to AuNPs produced by traditional chemical methods, the surfaces of the gold nanoparticles generated by the microplasma-induced liquid chemical process attracted more antibodies, which resulted in significantly higher detection sensitivity. A positive result yields reddish bands at both the test (T) and control (C) positions, whereas a negative result yields a reddish band at position C only. The level of cTn-I is below 0.06 ng/mL in the blood of healthy people, whereas the level of cTn-I may reach 100 ng/mL to 1,300 ng/mL in patients after the onset of acute myocardial infarction (AMI) and remains high for up to four to10 days.
The authors concluded that the immune-chromatography test assays for cTn-I prepared by AuNPs generated by plasma-liquid interaction exhibit higher detection sensitivity than those prepared by chemically reduced AuNPs detection. They believe that the microplasma-assisted synthesis of AuNPs have great potential for a variety of biomedical and therapeutic applications. The study was first published online on December 11, 2014, in the journal Plasma Processes and Polymers.
Related Links:
New York University Polytechnic School of Engineering
HyTest Ltd.
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more






 Analyzer.jpg)
